Literature DB >> 30114625

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.

Raphaël Bernard-Valnet1, Béatrice Pignolet2, Damien Biotti3, Jonathan Ciron3, Jean François Lafontan4, Hervé Dumas5, Fabrice Bonneville5, David Brassat6.   

Abstract

Unexpected high disease activity (UHDA) after Fingolimod withdrawal has recently become a controversial concern for physicians. Here, we report the case of a patient with severe exacerbation of MS after switching from Fingolimod to Alemtuzumab treatment. This UHDA despite profound lymphopenia raised the question of the management of sequential use of biotherapies such as Fingolimod and Alemtuzumab in MS.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Alemtuzumab; Fingolimod; Multiple Sclerosis; Rebound

Mesh：

Substances：

Year:  2018        PMID： 30114625     DOI： 10.1016/j.msard.2018.08.006

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


  5 in total

1.  Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Authors:  Jessica Frau; Francesco Saccà; Alessio Signori; Damiano Baroncini; Giuseppe Fenu; Pietro Annovazzi; Marco Capobianco; Elisabetta Signoriello; Alice Laroni; Sara La Gioia; Arianna Sartori; Giorgia Teresa Maniscalco; Simona Bonavita; Marinella Clerico; Cinzia Valeria Russo; Antonio Gallo; Caterina Lapucci; Antonio Carotenuto; Maria Pia Sormani; Eleonora Cocco
Journal:  J Neurol       Date:  2019-06-17       Impact factor: 4.849

2.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

3.  Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.

Authors:  Melanie Korsen; Steffen Pfeuffer; Leoni Rolfes; Sven G Meuth; Hans-Peter Hartung
Journal:  J Neurol       Date:  2022-01-09       Impact factor: 6.682

4.  A real-world study of alemtuzumab in a cohort of Italian patients.

Authors:  Cinzia Valeria Russo; Francesco Saccà; Jessica Frau; Pietro Annovazzi; Elisabetta Signoriello; Simona Bonavita; Roberta Grasso; Marinella Clerico; Cinzia Cordioli; Alice Laroni; Marco Capobianco; Valentina Torri Clerici; Arianna Sartori; Paola Cavalla; Giorgia Teresa Maniscalco; Sara La Gioia; Francesca Caleri; Alessia Giugno; Rosa Iodice; Antonio Carotenuto; Eleonora Cocco; Giuseppe Fenu; Mauro Zaffaroni; Damiano Baroncini; Giacomo Lus; Antonio Gallo; Stefania Federica De Mercanti; Caterina Lapucci; Valeria Di Francescantonio; Laura Brambilla; Maria Pia Sormani; Alessio Signori
Journal:  Eur J Neurol       Date:  2021-10-05       Impact factor: 6.288

5.  Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.

Authors:  D Ferraro; P Iaffaldano; T Guerra; M Inglese; M Capobianco; V Brescia Morra; M Zaffaroni; M Mirabella; G Lus; F Patti; P Cavalla; M Cellerino; S Malucchi; E Pisano; F Vitetta; D Paolicelli; P Sola; M Trojano
Journal:  J Neurol       Date:  2021-07-22       Impact factor: 4.849
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.